Prostate cancer is the most common cancer diagnosed in Victorian men, accounting for around a third (27%) of cases, with the number of new cases increasing each year. For many men, prostate cancer treatment involves significant side effects including urinary incontinence and sexual dysfunction, along with the emotional distress both a cancer diagnosis and the impact of treatment can cause. In an Australian first, Icon Cancer Centre is proud to launch the LIBERATE clinical registry in partnership with Epworth Healthcare, which aims to support the use of new precision focal brachytherapy for men with prostate cancer and reduce side effects to preserve their quality of life.
Focal brachytherapy is a highly-targeted technique which involves the implantation of small radioactive seeds directly into the cancerous area of the prostate. These seeds deliver radiation to destroy the cancer over a short period of time. Unlike traditional brachytherapy, the seeds are placed into the tumour rather than the whole prostate, preserving the rest of the prostate gland and limiting side effects.